CSIMarket Company Name, Ticker, Customers, else..
 
Neonc Technologies Holdings Inc   (NASDAQ: NTHI)
 
Price: $3.3000 $0.14 4.430%
Day's High: $3.5 Week Perf: 2.48 %
Day's Low: $ 3.12 30 Day Perf: -29.64 %
Volume (M): 180,592 52 Wk High: $ 12.99
Volume (M$): $ 0 52 Wk Avg: $6.85
Open: $3.35 52 Wk Low: $2.90



 Market Capitalization (Millions $) 81
 Shares Outstanding (Millions) 25
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -47
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Business Description


The company, formerly NAS-ONC, Inc., is a clinical-stage biopharmaceutical firm developing drugs and delivery methods for intracranial malignancies, including primary and secondary brain cancers. Its lead products, NEO100 and NEO212, utilize novel delivery approaches such as intranasal administration. Clinical trials are ongoing for malignant gliomas and skull-based meningiomas.


   Company Address: 23975 Park Sorrento Calabasas 91302 CA
   Company Phone Number: 663-7831   Stock Exchange / Ticker: NASDAQ NTHI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Partnership

On September 25, 2025, NeOnc Technologies Holdings, Inc. (NASDAQNTHI), a clinical-stage biotechnology compa...

Published Mon, Sep 22 2025 1:44 PM UTC

NeOnc Technologies to Highlight Advances in Brain Cancer Research on Nationwide TV Broadcast On September 25, 2025, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotechnology company specializing in therapies for central nervous system (CNS) cancers, will be featured on the health-oriented television program “Health Uncensored,” hosted by Dr. Drew Pi...
Product Service News

NeOnc Technologies Breaks New Ground with FDA Authorization of NEO212 Trials, Accelerating Brain Cancer Treatme...

Published Wed, Sep 10 2025 1:24 PM UTC

In a landmark announcement, NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has received authorization from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials for its pioneering oral chemotherapy candidate, NEO212. This first-in-class treatment is specifically designed for patients battling brain cancer, marking a significant step forward in ...
Product Service News

NeOnc Technologies Advances in Brain Cancer Battle with NEO212 Trial Nearing Phase I Completion,

Published Wed, Apr 9 2025 7:42 AM UTC

NeOnc Technologies Nears Completion of Phase I Enrollment for Promising Brain Cancer Therapy NeOnc Technologies, a biopharmaceutical company focusing on developing novel solutions for cancer treatment, has announced it is close to completing the Phase I enrollment for its innovative NEO212 therapy. This new treatment is specifically designed to combat brain cancer, a challen...
Management Changes

NeOnc Technologies: Shaping the Future of Brain Therapeutics with Strategic Leadership and Financial Backing

Published Tue, Mar 25 2025 12:01 PM UTC

Navigating New Frontiers in BiotechnologyNeOnc Technologies Holdings, Inc. is poised at an exciting juncture in its corporate evolution, marked by significant leadership appointments, strategic financing, and a forthcoming listing on the Nasdaq Global Market. These developments collectively herald a promising trajectory for the biotech company, known for its pioneering work...
Stock Market Announcement

NeOnc Technologies Poised for Growth: Nasdaq Listing and Promising Advances in Brain Therapeutics

Published Tue, Mar 25 2025 8:30 PM UTC

In a strategic move for expansion and innovation, NeOnc Technologies prepares for a significant milestone that is likely to shape its future trajectory. The biotechnology company, renowned for its innovative approaches to treating neurological disorders, has announced its anticipated listing on the Nasdaq Global Market on March 26, under the symbol NTHI. This pivotal step un...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.15
Working Capital Ratio 0.24
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.21 $
Revenues (TTM) -
Cash Flow (TTM) 0 $
Cash 0.14 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -9,440,000
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.